NASDAQ:SLDB - Nasdaq - US83422E2046 - Common Stock - Currency: USD
2.89
+0.19 (+7.04%)
The current stock price of SLDB is 2.89 USD. In the past month the price decreased by -21.25%. In the past year, price decreased by -62.9%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.77 | 322.91B | ||
AMGN | AMGEN INC | 13.1 | 146.19B | ||
GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
NTRA | NATERA INC | N/A | 20.73B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
BIIB | BIOGEN INC | 7.98 | 18.51B |
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The firm also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. The company also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
SOLID BIOSCIENCES INC
500 Rutherford Avenue, 3rd Floor
Charlestown MASSACHUSETTS 02139 US
CEO: Ilan Ganot
Employees: 100
Phone: 16173374680
The current stock price of SLDB is 2.89 USD. The price increased by 7.04% in the last trading session.
The exchange symbol of SOLID BIOSCIENCES INC is SLDB and it is listed on the Nasdaq exchange.
SLDB stock is listed on the Nasdaq exchange.
18 analysts have analysed SLDB and the average price target is 17.68 USD. This implies a price increase of 511.76% is expected in the next year compared to the current price of 2.89. Check the SOLID BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SOLID BIOSCIENCES INC (SLDB) has a market capitalization of 223.97M USD. This makes SLDB a Micro Cap stock.
SOLID BIOSCIENCES INC (SLDB) currently has 100 employees.
SOLID BIOSCIENCES INC (SLDB) has a support level at 2.59 and a resistance level at 2.96. Check the full technical report for a detailed analysis of SLDB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SLDB does not pay a dividend.
SOLID BIOSCIENCES INC (SLDB) will report earnings on 2025-08-11, before the market open.
SOLID BIOSCIENCES INC (SLDB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.04).
The outstanding short interest for SOLID BIOSCIENCES INC (SLDB) is 10.91% of its float. Check the ownership tab for more information on the SLDB short interest.
ChartMill assigns a fundamental rating of 2 / 10 to SLDB. SLDB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months SLDB reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS increased by 36.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -39.26% | ||
ROE | -46.93% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to SLDB. The Buy consensus is the average rating of analysts ratings from 18 analysts.